Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Rankning i aktier #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Aktiekurs
$17.15
Senast synkroniserad: 2026-08-03
Marknadsvärde
$6.51M
Förändring (1 dag)
9.80%
Förändring (1 år)
289.77%
Land
US
Handel Galera Therapeutics, Inc. (GRTX)

Kategori

Vinst för Galera Therapeutics, Inc. (GRTX)
Vinst i Mar 2026 TTM: $149.04M
Enligt de senaste finansiella rapporterna från Galera Therapeutics, Inc. är företagets nuvarande vinst $149.04M. År 2023 hade företaget en vinst på $-59.08M, en ökning jämfört med vinsten år 2022 som var $-62.29M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Galera Therapeutics, Inc. från 2017 till 2026
Vinst vid slutet av varje år
År Vinst Ändra
2026 (TTM) $149.04M -877.84%
2024 $-19.16M -67.57%
2023 $-59.08M -5.15%
2022 $-62.29M -22.65%
2021 $-80.53M 8.49%
2020 $-74.23M 42.93%
2019 $-51.94M 117.33%
2018 $-23.90M -0.03%
2017 $-23.91M 0.00%
Vinst för liknande företag eller konkurrenter
Företag Vinst Skillnad i vinst Land
$5.27B 3,439.37%
US
$1.95B 1,208.85%
NL
- -
CH
- -
KR
$3.01B 1,916.79%
BE